Pseudomonas exotoxin a-like chimeric immunogens
AssigneeThe Gov. of the USA as Represented by the Secretary of the Dept.of Health & human Services
InventorDavid J. FitzGerald
Life of this patent
Estimating the term…
Abstract
This invention provides Pseudomonas exotoxin A-like chimeric immunogens that include a non-native epitope in the Ib domain of Pseudomonas exotoxin. Methods of eliciting an immune response using these immunogens also are provided.
Claims27
A non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen comprising:
- (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor;
- (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol;
- and (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope.
(canceled)
(canceled)
(canceled)
A recombinant polynucleotide comprising a nucleotide sequence encoding a non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen, the PE-like chimeric immunogen comprising:
- (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor;
- (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol;
- and (3) a non-native epitope domain comprising an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope.
A recombinant non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen cloning platform comprising a nucleotide sequence encoding:
- (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor;
- (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol;
- and (3) a splicing site between the sequence encoding the translocation domain and the sequence encoding the ER retention domain.
A method of producing antibodies against a non-native epitope, wherein the non-native epitope naturally exists within a cysteine-cysteine loop comprising the step of inoculating an animal with a non-toxic Pseudomonas exotoxin A-like (“PE-like”) chimeric immunogen, the PE-like chimeric immunogen comprising:
- (1) a cell recognition domain of between 10 and 1500 amino acids that binds to a cell surface receptor;
- (2) a translocation domain comprising an amino acid sequence substantially identical to a sequence of PE domain II sufficient to effect translocation to a cell cytosol;
- and a (3) a non-native epitope domain comprising a cysteine-cysteine loop that contains within the loop an amino acid sequence of between 5 and 1500 amino acids that encodes a non-native epitope.
27-43. (canceled)
Dependencies are inferred from the claim text.